CRISPR has successfully inactivated the mutant HTT gene in patient-derived fibroblasts (Shin et al. 2016), HD mouse models (Monteys et al. 2017), and human-induced pluripotent stem cells (Heman-Ackah et al. 2016). This evidence concerns the gene HTT and Huntington disease.